|
[1] YKI-JRVINEN H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome[J]. Lancet Diabetes Endocrinol,2014,2(11):901-910.
|
|
[2] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.
|
|
[3] PAIS R,BARRITT AS 4th,CALMUS Y,et al. NAFLD and liver transplantation:Current burden and expected challenges[J].J Hepatol,2016,65(6):1245-1257.
|
|
[4] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes[J]. Hepatology,2016,64(1):73-84.
|
|
[5] ZHOU F,ZHOU J,WANG W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and Meta-analysis[J]. Hepatology,2019,70(4):1119-1133.
|
|
[6] FAN JG,KIM SU,WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol,2017,67(4):862-873.
|
|
[7] CHANG Y,JUNG HS,CHO J,et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease[J]. Am J Gastroenterol,2016,111(8):1133-1140.
|
|
[8] KOO BK,KIM D,JOO SK,et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis[J]. J Hepatol,2017,66(1):123-131.
|
|
[9] WONG VW,WONG GL,TSE CH,et al. Prevalence of the TM6SF2variant and non-alcoholic fatty liver disease in Chinese[J]. J Hepatol,2014,61(3):708-709.
|
|
[10] LI Y,XU C,YU C,et al. Association of serum uric acid level with non-alcoholic fatty liver disease:A cross-sectional study[J]. J Hepatol,2009,50(5):1029-1034.
|
|
[11] CUSI K,SANYAL AJ,ZHANG S,et al. Non-alcoholic fatty liver disease(NAFLD)prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes[J].Diabetes Obes Metab,2017,19(11):1630-1634.
|
|
[12] TARGHER G,BYRNE CD,LONARDO A,et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease:A meta-analysis[J]. J Hepatol,2016,65(3):589-600.
|
|
[13] ESLAM M,VALENTI L,ROMEO S. Genetics and epigenetics of NAFLD and NASH:Clinical impact[J]. J Hepatol,2018,68(2):268-279.
|
|
[14] WU Z,BOSS O. Targeting PGC-1 alpha to control energy homeostasis[J]. Expert Opin Ther Targets,2007,11(10):1329-1338.
|
|
[15] FANELLI M,FILIPPI E,SENTINELLI F,et al. The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha(PGC-1 alpha)gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects[J]. Dis Markers,2005,21(4):175-180.
|
|
[16] DU Q,TAN Z,SHI F,et al. PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation[J]. Cancer Sci,2019,110(6):2050-2062.
|
|
[17] YANG S,HWANG S,JANG J,et al. PGC1αis required for the induction of contact inhibition by suppressing ROS[J].Biochem Biophys Res Commun,2018,501(3):739-744.
|
|
[18] QIAN J,CHEN S,HUANG Y,et al. PGC-1αregulates hepatic hepcidin expression and iron homeostasis in response to inflammation[J]. Mol Endocrinol,2013,27(4):683-692.
|
|
[19] YONEDA M,HOTTA K,NOZAKI Y,et al. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease(NAFLD)[J]. BMC Gastroenterol,2008,8:27.
|
|
[20] MORADI S,MIRZAEI K,MAGHBOOLI Z,et al. Variants in the PPARGC1A gene may influence the effect of fat intake on resting metabolic rate in obese women[J]. Lipids,2018,53(3):291-300.
|
|
[21] Group of Fatty Liver and Alcoholic Liver Diseases,Society of Hepatology,Chinese Medical Association. Guidelines for Management of non-alcoholic fatty liver disease[J]. J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组．非酒精性脂肪性肝病诊疗指南[J]．临床肝胆病杂志，2010,26(2):120-124.
|
|
[22] PICCININ E,VILLANI G,MOSCHETTA A. Metabolic aspects in NAFLD,NASH and hepatocellular carcinoma:The role of PGC1 coactivators[J]. Nat Rev Gastroenterol Hepatol,2019,16(3):160-174.
|
|
[23] NITZ I,EWERT A,KLAPPER M,et al. Analysis of PGC-1alpha variants Gly482Ser and Thr612Met concerning their PPARgamma2-coactivation function[J]. Biochem Biophys Res Commun,2007,353(2):481-486.
|
|
[24] BESSE-PATIN A,LéVEILLéM,OROPEZA D,et al. Estrogen signals through peroxisome proliferator-activated receptor-γcoactivator 1αto reduce oxidative damage associated with diet-induced fatty liver disease[J]. Gastroenterology,2017,152(1):243-256.
|
|
[25] CHEN Y,MU P,HE S,et al. Gly482Ser mutation impairs the effects of peroxisome proliferator-activated receptorγcoactivator-1αon decreasing fat deposition and stimulating phosphoenolpyruvate carboxykinase expression in hepatocytes[J]. Nutr Res,2013,33(4):332-339.
|
|
[26] KOZAKOVA M,PALOMBO C,ENG MP,et al. Fatty liver index,gamma-glutamyltransferase,and early carotid plaques[J]. Hepatology,2012,55(5):1406-1415.
|
|
[27] XU Y,BI YF,XU M,et al. Cross-sectional and longitudinal association of serum alanine aminotransaminase andγ-glutamyltransferase with metabolic syndrome in middle-aged and elderly Chinese people[J]. J Diabetes,2011,3(1):38-47.
|
|
[28] BOTTON J,HEUDE B,ANDRE P,et al. Relationship between gamma-glutamyltransferase and fat mass in a general population of 8-17 years old children. The FLVS II study[J]. Diabetes Metab,2007,33(5):354-359.
|
DownLoad: